Search results
Head to Head Survey: Cognition Therapeutics (NASDAQ:CGTX) vs. Opthea (NASDAQ:OPT)
ETF DAILY NEWS· 3 days agoCognition Therapeutics (NASDAQ:CGTX – Get Free Report) and Opthea (NASDAQ:OPT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the ...
The Truth Behind Fake Meat
Mercola· 4 days agoA 2024 systematic review1 of the literature confirmed what multiple studies have shown — the higher your intake of ultraprocessed food, the higher your risk of adverse health outcomes. The analysis ...
Court to hear case over 2018 car crash that killed 5-year-old Decatur boy
WAGA fox local articles via Yahoo News· 7 days agoProsecutors say the Georgia psychiatrist should be held accountable for her actions that caused the...
24 Things You Really to Know About Osteoporosis, Regardless of Your Age
MediaFeed via AOL· 3 days agoNo matter your age, you can take steps to build bone mass and prevent bone loss. Broken bones from...
ADVERTISING: Advertorial — What’s causing my pain?
Coeur d'Alene Press· 7 days agoAt Natural Spine Solutions, we treat people with chronic pain every day and Dr. Fichter focuses on the underlying cause of the pain. When working with patients that have chronic pain, it is ...
6 Signs Your Memory Loss Isn't Normal
The Huffington Post· 4 days agoGetting older goes hand in hand with forgetfulness — like not remembering the name of the new restaurant in town or misplacing your glasses. “Some degree...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
St. Louis Post-Dispatch· 5 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT ...
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Morningstar· 5 days agoCommercial launch of INPEFA® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing ...
What's Behind Major Rise in Heart Failure Deaths?
WebMD· 5 days agoDuring the pandemic years of 2020 and 2021, the latest year for which data is available, heart failure deaths accelerated. “These data are striking,” said Veronique Roger, MD, MPH, chief of ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
FOX 4 Kansas City· 5 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study...
